Immunotherapy before surgery for MSI-H colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy before surgery, with or without radiation, can help shrink locally advanced colorectal cancer that has a specific genetic marker (MSI-H or dMMR). It aims to improve outcomes for patients who have not yet had any treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of colorectal cancer that has not spread far (stage II or III).
- Your tumor has a specific genetic feature called MSI-H or dMMR (your doctor can check).
- You are at least 18 years old.
- You are in good enough health to undergo treatment (ECOG score 0 or 1).
- You have not had any prior treatment for this cancer (no surgery, chemo, or radiation yet).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial studies whether immunotherapy (nivolumab plus ipilimumab) can help people with early-stage rectal cancer that has dMMR or MSI changes. It’s meant for patients who have not yet had chemotherapy, radiation, or immunotherapy for colorectal cancer.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.